Post Profile






Sage shares surge as depression drug succeeds in mid-stage trial

(Reuters) - Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.
read more

share

Related Posts


Flexion's knee pain drug gets FDA nod, shares hit life high

Health : Reuters: Health

(Reuters) - Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular t...

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Health : Reuters: Health

(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study.

Sage's seizure drug fails key trial, shares slump

Health : Reuters: Health

(Reuters) - Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.

Sage soars as postpartum depression drug moves closer to approval

Health : Reuters: Health

(Reuters) - Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the di...

Sage shares rise after postpartum depression drug meets main goal

Health : Reuters: Health

(Reuters) - Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression succeeded in reducing symptoms in patients enrolled in two late-stage trials, sending its shares up 50 percent in pre-market ...

Comments


Copyright © 2016 Regator, LLC